Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

• Sponsor: Xeris Pharmaceuticals (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04074317
• Collaborator: (none)
• Enrollment: 18
• Location: 1
• Arms: 3
• Actual Duration (Months): 7.4
• Patients Per Site Per Month: 2.4

Study Details

Study Description

Brief Summary

This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D. The study comprises 5 visits: Screening (Visit 1), Treatment Periods (Visits 2 - 4), and Follow-Up (Visit 5).

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus, Type 1; Insulin-dependent Diabetes Mellitus	Drug: PRAM9; Drug: Regular Insulin + Pramlintide; Drug: Regular Insulin	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 18 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus
• Actual Study Start Date: Aug 22, 2019
• Actual Primary Completion Date: Apr 2, 2020
• Actual Study Completion Date: Apr 2, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: PRAM9 Xeris pramlintide + insulin co-formulation	Drug: PRAM9; SC injection; Drug: Regular Insulin + Pramlintide; Separate SC injections; Drug: Regular Insulin; SC injection
Experimental: Regular Insulin + Pramlintide Humulin® + Symlin® pen as separate injections	Drug: PRAM9; SC injection; Drug: Regular Insulin + Pramlintide; Separate SC injections; Drug: Regular Insulin; SC injection
Active Comparator: Regular Insulin Humulin®	Drug: PRAM9; SC injection; Drug: Regular Insulin + Pramlintide; Separate SC injections; Drug: Regular Insulin; SC injection

Outcome Measures

Primary Outcome Measures

1. Area under the curve 0-180 minutes [0-180 minutes following administration of study drug]

Secondary Outcome Measures

1. Glucose time above 180 mg/dL [0-180 minutes following administration of study drug]

2. Glucose time in range [0-180 minutes following administration of study drug]

3. Plasma glucose maximum concentration (Cmax) [0-180 minutes following administration of study drug]

4. Plasma glucose time to maximum concentration (Tmax) [0-180 minutes following administration of study drug]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 64 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Understands the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agrees to participate by giving written informed consent

2. Male or non-pregnant, non-lactating female diagnosed with T1D for at least 24 months prior to Screening.

3. Aged 18 to 64 years of age, inclusive

4. On a stable insulin regimen for 21 days prior to Screening (no greater than ± 20% variability in total daily dose)

5. Have a plasma C-peptide level < 0.6 ng/mL at Screening

6. Have an HbA1c < 10% at Screening

7. Body mass index (BMI) in the range of ≥ 18 to ≤ 35 kg/m2 at Screening

8. For women of childbearing potential, there is a requirement for a negative urine pregnancy test at Screening and for agreement to use contraception throughout the study and for 7 days after the last dose of study drug. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera® (medroxyprogesterone acetate), Norplant® System (levonorgestrel), an intra-uterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.

9. Fasting Serum triglyceride concentration < 200 mg/dL

Exclusion Criteria:

1. Currently being treated with pramlintide or has discontinued pramlintide within 21 days of Screening

2. Currently using an insulin pump

3. Has renal insufficiency (serum creatinine > 3.0 mg/dL) or end-stage renal disease requiring renal replacement therapy

4. Has hepatic disease, including serum ALT or AST ≥ 3 times the upper limit of normal (ULN)

5. Has hepatic synthetic insufficiency (serum albumin < 3.0 g/dL) Has hematocrit ≤ 30%

6. Has hematocrit ≤ 30%

7. Has out-of-range systolic or diastolic BP readings at Screening (systolic BP < 90 or > 150 mm Hg or diastolic BP < 50 or > 100 mm Hg)

8. Has clinically significant ECG abnormalities at Screening

9. Has congestive heart failure, NYHA Class III or IV

10. Has history of myocardial infarction, unstable angina, or revascularization within 6 months prior to Screening

11. Has history of a cerebrovascular accident in 6 months prior to Screening with major neurological deficits

12. Has active malignancy within 5 years prior to Screening (exception: basal cell or squamous cell skin cancers)

13. Has had major surgical operation within 60 days prior to Screening or planned surgical operation during the study

14. Has a seizure disorder (other than with suspected or documented hypoglycemia)

15. Has a current bleeding disorder, treatment with anticoagulants, or platelet count < 50 ×109/L

16. Has a history of allergies or significant hypersensitivity to pramlintide or any pramlintide-related products or to any of the excipients in the investigational formulation

17. Has a history of positive test result for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)

18. Has a concurrent illness not controlled by a stable therapeutic regimen

19. Tests positive for drugs of abuse at Screening. Subjects testing positive for tetrahydrocannabinol (THC) at Screening or reporting active marijuana use will be allowed to participate in the study at the discretion of the investigator.

20. Has active substance or alcohol abuse (> 21 drinks/week for males or > 14 drinks/week for females)

21. Has participated in other studies involving administration of an investigational drug within 30 days or 5 half-lives prior to Screening (whichever is longer) or during participation in the current study

22. There is any reason the investigator deems exclusionary

23. Has donated blood within 8 weeks prior to Screening.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	World Wide Clinical Trials	San Antonio	Texas	United States	78217

Sponsors and Collaborators

• Xeris Pharmaceuticals

Investigators

• Study Director: Andrea Valasquez, Worldwide Clinical Trials
• Principal Investigator: George Atiee, Worldwide Clinical Trials

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Xeris Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT04074317
• Other Study ID Numbers: DPI-201
• First Posted: Aug 30, 2019
• Last Update Posted: May 28, 2020
• Last Verified: May 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 1; Insulin; Insulin, Globin Zinc; Pramlintide

Study Results

No Results Posted as of May 28, 2020